Go to the list of all blogs
Sergey Savastiouk's Avatar
published in Blogs
Oct 29, 2026
TickeronGET DAILY SIGNALS
DexCom (DXCM) Reports 11% Revenue Growth in Q3 2026, Raises Full-Year Outlook

DexCom (DXCM) Reports 11% Revenue Growth in Q3 2026, Raises Full-Year Outlook

Key Takeaways

  • DexCom reported third quarter 2026 revenue of $1.34 billion, up 11% year over year on both a reported and organic basis.
  • Adjusted (non-GAAP) earnings per share came in at $0.73, beating the analyst consensus estimate of $0.67 by roughly 8%.
  • U.S. revenue grew 14% to about $970 million, while international revenue rose 5% to roughly $375 million.
  • Management raised its full-year 2026 revenue guidance to $5.20–$5.25 billion, implying 12%–13% growth.
  • Non-GAAP operating margin expanded to approximately 24%, and adjusted EBITDA margin reached about 32%.
  • Shares climbed roughly 2% in after-hours trading following the release.

Why These Results Matter

DexCom stands out as a leader in continuous glucose monitoring systems that allow people with diabetes to track levels in real time. Its quarterly updates serve as a useful gauge of demand for diabetes technology and the company's efforts to broaden access. After a solid first half of 2026, attention turned to whether growth could hold in double digits, market share could be defended, and margins could keep improving. The quarter also highlighted potential reimbursement changes, especially around Medicare coverage for certain type 2 diabetes patients, which could expand the long-term opportunity.

Q3 Results in Detail

For the period ended September 30, 2026, total revenue reached $1.34 billion, an 11% increase from $1.21 billion a year earlier. U.S. sales hit roughly $970 million, up 14%, while international revenue came in near $375 million, up 5%. Slower international growth stemmed mainly from tough prior-year comparisons tied to reimbursement gains rather than any fundamental slowdown.

Adjusted earnings per share of $0.73 topped the $0.67 consensus. GAAP diluted EPS was $0.72. Adjusted EBITDA totaled $435.2 million, ahead of the roughly $424 million expected. Non-GAAP operating margin rose to about 24%, helped by manufacturing gains, lower freight costs, and the contribution from the G7 15-day sensor. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.

Full-year 2026 revenue guidance was lifted to $5.20–$5.25 billion from the prior $5.18–$5.25 billion range, with non-GAAP operating margin held near 24%.

Market Response and Outlook

Shares moved up about 2% in after-hours trading after the October 29 release. The reaction reflected the earnings beat, slight revenue outperformance, and the raised guidance. From what I see, investors viewed the results as confirmation that growth momentum remains steady despite lapping stronger international comparisons from last year.

Comments on reimbursement added support, with expectations for a CMS decision on coverage for non-insulin type 2 diabetes patients this year and possible rollout in mid-2027. Clinical data from the CONNECT trial, published in the New England Journal of Medicine, further bolstered the longer-term case.

Looking ahead, the G7 15-day rollout should continue driving revenue and margins, with nearly half of U.S. customers expected to convert by year-end. International launches are set for Canada in November and Japan early next year. Reimbursement expansion remains a key catalyst, while margin trends should benefit from efficiencies and normalized costs at the Ireland facility. The pipeline, including a next-generation sensor and the Stelo over-the-counter option, offers additional growth avenues, though foreign exchange and competition will stay in focus.

AI Tools in My Research Process

When analyzing earnings like these, I often turn to Tickeron’s AI-powered tools to quickly scan for patterns and compare performance across peers. The AI Screener helps surface relevant data points efficiently, and I’ve found the AI Daily Buy/Sell Signals and AI Trend Prediction Engine useful for gauging momentum in real time. These resources fit naturally into a broader review without replacing fundamental analysis.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: DXCM

Contributor

Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.


DXCM in upward trend: price expected to rise as it breaks its lower Bollinger Band on October 21, 2026

DXCM may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In 25 of 35 cases where DXCM's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are 71%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where DXCM's RSI Indicator exited the oversold zone, 22 of 33 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 67%.

The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 2 days, which means it's wise to expect a price bounce in the near future.

Following a +1.11% 3-day Advance, the price is estimated to grow further. Considering data from situations where DXCM advanced for three days, in 200 of 295 cases, the price rose further within the following month. The odds of a continued upward trend are 68%.

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on November 16, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on DXCM as a result. In 58 of 89 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 65%.

The Moving Average Convergence Divergence Histogram (MACD) for DXCM turned negative on November 20, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 46 similar instances when the indicator turned negative. In 33 of the 46 cases the stock turned lower in the days that followed. This puts the odds of success at 72%.

DXCM moved below its 50-day moving average on November 05, 2026 date and that indicates a change from an upward trend to a downward trend.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where DXCM declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 74%.

The Aroon Indicator for DXCM entered a downward trend on October 28, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron SMR rating for this company is 27 (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Price Growth Rating for this company is 45 (best 1 - 100 worst), indicating steady price growth. DXCM’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron PE Growth Rating for this company is 55 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Valuation Rating of 83 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (11.431) is normal, around the industry mean (4.142). P/E Ratio (30.779) is within average values for comparable stocks, (3.291). Projected Growth (PEG Ratio) (1.332) is also within normal values, averaging (11.253). Dividend Yield (0.000) settles around the average of (0.011) among similar stocks. P/S Ratio (6.988) is also within normal values, averaging (40.124).

The Tickeron Seasonality Score of 85 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. DXCM’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

Notable companies

The most notable companies in this group are Abbott Laboratories (NYSE:ABT), Medtronic plc (NYSE:MDT), Boston Scientific Corp (NYSE:BSX), Edwards Lifesciences Corp (NYSE:EW).

Industry description

The medical/nursing services includes companies that provide medical-related services such as ambulance services, dialysis centers, respiratory therapy, blood testing and rehabilitation services. DaVita Inc., Chemed Corporation and Guardant Health, Inc. are examples of companies in this industry.

Market Cap

The average market capitalization across the Medical/Nursing Services Industry is 6.17B. The market cap for tickers in the group ranges from 837 to 190.22B. ABT holds the highest valuation in this group at 190.22B. The lowest valued company is DHAI at 837.

High and low price notable news

The average weekly price growth across all stocks in the Medical/Nursing Services Industry was -11%. For the same Industry, the average monthly price growth was -15%, and the average quarterly price growth was -18%. MXCT experienced the highest price growth at 15%, while CODX experienced the biggest fall at -50%.

Volume

The average weekly volume growth across all stocks in the Medical/Nursing Services Industry was -35%. For the same stocks of the Industry, the average monthly volume growth was -2% and the average quarterly volume growth was -21%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 48
P/E Growth Rating: 50
Price Growth Rating: 64
SMR Rating: 89
Profit Risk Rating: 94
Seasonality Score: 16 (-100 ... +100)
AI Screener 3
View a ticker or compare two or three
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

a maker of medical devices and glucose monitoring systems

Industry MedicalNursingServices

Industry
Medical Specialties
Address
6340 Sequence Drive
Phone
+1 858 200-0200
Employees
11100
Web
https://www.dexcom.com
Interact to see
Advertisement
Alphabet Inc. (GOOG) , the parent of Google, YouTube, and Google Cloud, is a common stock, not an exchange-traded fund. The central target of $400 is the arithmetic mean of current analyst price targets, which span a wide band from roughly $300 to $500, with the broad average near $397.
AAPL has shown stronger relative performance in recent weeks, holding near record highs while many artificial intelligence (AI)-focused tech stocks sold off. MSFT has lagged the market and now trades below its 50-day moving average amid concerns over heavy AI infrastructure spending.
Bending Spoons reported third-quarter 2026 revenue of $780.22 million, up 125.1% year over year and above the roughly $745.86 million consensus estimate. Earnings per share (EPS) came in at $0.42, beating the $0.26 consensus estimate by $0.16.
GOOG declined roughly 20% over the past 30 days, falling from about $331 to around $264 per share. The sell-off was triggered by Alphabet's third-quarter 2026 report, which revealed slowing Search advertising growth and an earnings miss.
Intel Corporation has delivered dramatically stronger relative price momentum over the past year, while SPY offers broad, diversified market exposure with far lower single-stock volatility. INTC's rally has been driven by a strategic turnaround under new leadership, backed by multi-billion-dollar investments from Nvidia, SoftBank, and the U.S. government.